Stay updated with breaking news from Study Comparing Risankizumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and... | October 3, 2021
AbbVie today announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two ...
/PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative...
/PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative...
Phase 3 Maintenance Results Show Patients with Crohn's Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year - In Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1] - The overall safety results in this study were generally consistent with the known safety profile of risankizumab, w...